[FG] Marzolini Catia

Marzolini, Catia et al. (2025) ‘Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir’, Expert Opinion on Drug Metabolism and Toxicology, 21(2), pp. 161–172. Available at: https://doi.org/10.1080/17425255.2024.2415295.

Pham, Thao et al. (2024) ‘DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy’, npj Systems Biology and Applications, 10(1). Available at: https://doi.org/10.1038/s41540-024-00374-0.

Berton, Mattia et al. (2024) ‘Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure’, Open Forum Infectious Diseases, 11(10), p. 11. Available at: https://doi.org/10.1093/ofid/ofae585.

Abela, Irene A et al. (2024) ‘Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk’, Open Forum Infectious Diseases, 11(9). Available at: https://doi.org/10.1093/ofid/ofae502.

Haefliger, David et al. (2024) ‘Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report’, Seminars in Dialysis, 37(6), pp. 461–465. Available at: https://doi.org/10.1111/sdi.13224.

Bettonte, Sara et al. (2024) ‘Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study’, Clinical Infectious Diseases, 79(2), pp. 477–486. Available at: https://doi.org/10.1093/cid/ciae060.

Bongiovanni, Marco et al. (2024) ‘Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations’, European Journal of Clinical Microbiology and Infectious Diseases, 43(7), pp. 1503–1504. Available at: https://doi.org/10.1007/s10096-024-04844-5.

Thoueille, Paul et al. (2024) ‘Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV’, Clinical Pharmacology and Therapeutics, 115(6), pp. 1450–1459. Available at: https://doi.org/10.1002/cpt.3240.

Bettonte, Sara et al. (2024) ‘Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs’, CPT: Pharmacometrics and Systems Pharmacology, 13(5), pp. 781–794. Available at: https://doi.org/10.1002/psp4.13118.

Bettonte, Sara et al. (2024) ‘Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study’, Open Forum Infectious Diseases, 11(4). Available at: https://doi.org/10.1093/ofid/ofae171.

Briki, M. et al. (2024) ‘Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update’, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1236, p. 124039. Available at: https://doi.org/10.1016/j.jchromb.2024.124039.

Thoueille, Paul et al. (2024) ‘Population pharmacokinetic analysis of doravirine in real-world people with HIV’, British Journal of Clinical Pharmacology, 90(4), pp. 1058–1065. Available at: https://doi.org/10.1111/bcp.15975.

Ambrosioni, Juan et al. (2024) ‘Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study’, Infectious Diseases and Therapy, 13(3), pp. 609–617. Available at: https://doi.org/10.1007/s40121-024-00935-0.

Thoueille, Paul et al. (2024) ‘Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures’, Open Forum Infectious Diseases, 11(2). Available at: https://doi.org/10.1093/ofid/ofae023.

Berton, Mattia et al. (2024) ‘Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data’, Clinical Infectious Diseases, 78(1), pp. 98–110. Available at: https://doi.org/10.1093/cid/ciad495.

Amstutz, Alain et al. (2024) ‘Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study’, Journal of Infectious Diseases, 230, pp. e847–e859. Available at: https://doi.org/10.1093/infdis/jiae291.

Begré, Lorin et al. (2024) ‘Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy’, Journal of Infectious Diseases, 230, pp. e954–e963. Available at: https://doi.org/10.1093/infdis/jiae189.

Damas, José et al. (2024) ‘Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV’, Clinical Infectious Diseases, 79, pp. 990–998. Available at: https://doi.org/10.1093/cid/ciae189.

Katende, Andrew et al. (2024) ‘Use of a Handheld Ultrasonographic Device to Identify Heart Failure and Pulmonary Disease in Rural Africa’, JAMA Network Open, 7, p. E240577. Available at: https://doi.org/10.1001/jamanetworkopen.2024.0577.

Katende, Andrew et al. (2024) ‘Recovery of left ventricular systolic function in peripartum cardiomyopathy: an observational study from rural Tanzania’, BMC Cardiovascular Disorders, 24. Available at: https://doi.org/10.1186/s12872-024-03906-y.

Pasin, Chloé et al. (2024) ‘Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities’, HIV Medicine, 25, pp. 1112–1124. Available at: https://doi.org/10.1111/hiv.13677.

Thoueille, Paul et al. (2024) ‘Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland’, The Lancet Regional Health - Europe, 36. Available at: https://doi.org/10.1016/j.lanepe.2023.100793.

Weber, M.S.R. et al. (2024) ‘Time Trends in Causes of Death in People With HIV: Insights From the Swiss HIV Cohort Study’, Clinical Infectious Diseases, 79, pp. 177–188. Available at: https://doi.org/10.1093/cid/ciae014.

Bettonte S et al. (2023) ‘Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen’, British Journal of Clinical Pharmacology, 89(12), pp. 3618–3628. Available at: https://doi.org/10.1111/bcp.15867.

Erba A et al. (2023) ‘Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient’, Virology Journal, 20(1), p. 89. Available at: https://doi.org/10.1186/s12985-023-02058-3.

Ambrosioni, Juan et al. (2023) ‘Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023’, HIV Medicine, 24(11), pp. 1126–1136. Available at: https://doi.org/10.1111/hiv.13542.

Cortés, K.C. et al. (2023) ‘T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C’, Open Forum Infectious Diseases, 10(11). Available at: https://doi.org/10.1093/ofid/ofad514.

Sebastiani G et al. (2023) ‘Letter to the Editor: People living with HIV and NAFLD—A population left behind in the global effort for liver fibrosis screening?’, Hepatology, 78(5), pp. E87–E88. Available at: https://doi.org/10.1097/HEP.0000000000000465.

Schwenke, Johannes M et al. (2023) ‘Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study’, Journal of Infectious Diseases, 228(6), pp. 742–750. Available at: https://doi.org/10.1093/infdis/jiad179.

Marzolini C et al. (2023) ‘Effect of SLCO1B1 c.521T> C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen’, British Journal of Clinical Pharmacology, 89(9), pp. 2739–2746. Available at: https://doi.org/10.1111/bcp.15754.

Paioni P. et al. (2023) ‘Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study’, The Lancet Regional Health - Europe, 31. Available at: https://doi.org/10.1016/j.lanepe.2023.100656.

Berton M et al. (2023) ‘Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers’, Open Forum Infectious Diseases, 10(7), p. ofad361. Available at: https://doi.org/10.1093/ofid/ofad361.

Bettonte S et al. (2023) ‘Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates’, European Journal of Drug Metabolism and Pharmacokinetics, 48(4), pp. 353–362. Available at: https://doi.org/10.1007/s13318-023-00833-9.

Haefliger D et al. (2023) ‘Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole’, British Journal of Clinical Pharmacology. John Wiley and Sons Inc, 89(7). Available at: https://doi.org/10.1111/bcp.15743.

Otte, Fabian et al. (2023) ‘Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods’, Cell Reports Methods, 3(6). Available at: https://doi.org/10.1016/j.crmeth.2023.100485.

Avery Emma F et al. (2023) ‘Leukocyte Count and Coronary Artery Disease Events in People with Human Immunodeficiency Virus: A Longitudinal Study’, Clinical Infectious Diseases, 76(11), pp. 1969–1979. Available at: https://doi.org/10.1093/cid/ciad033.

Avery, Emma F et al. (2023) ‘Leukocyte Count and Coronary Artery Disease Events in People with Human Immunodeficiency Virus: A Longitudinal Study’, Clinical Infectious Diseases, 76(11), pp. 1969–1979. Available at: https://doi.org/10.1093/cid/ciad033.

Schoepf, Isabella C et al. (2023) ‘Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years’, The Lancet Healthy Longevity, 4(5), pp. e211–e218. Available at: https://doi.org/10.1016/S2666-7568(23)00037-5.

Schoepf, Isabella C et al. (2023) ‘Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years’, The Lancet Healthy Longevity, 4(5), pp. e211–e218. Available at: https://doi.org/10.1016/s2666-7568(23)00037-5.

Surial, B. et al. (2023) ‘External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection’, Journal of Hepatology, 78(5), pp. 947–957. Available at: https://doi.org/10.1016/j.jhep.2022.12.029.

Bettonte S et al. (2023) ‘Management of Drug-Drug Interactions between Long-Acting Cabotegravir and Rilpivirine and Comedications with Inducing Properties: A Modeling Study’, Clinical Infectious Diseases, 76(7), pp. 1225–1236. Available at: https://doi.org/10.1093/cid/ciac901.

Marzolini C and Khoo S (2023) ‘Response to “A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir”’, Clinical Pharmacology and Therapeutics, 113(4). Available at: https://doi.org/10.1002/cpt.2809.

Hofmann, Eveline et al. (2023) ‘Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection’, Clinical Infectious Diseases, 76(4), pp. 730–733. Available at: https://doi.org/10.1093/cid/ciac823.

Labarile, Marco et al. (2023) ‘Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach’, Journal of Infectious Diseases, 227(4), pp. 554–564. Available at: https://doi.org/10.1093/infdis/jiac457.

Berton M et al. (2023) ‘Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals’, Clinical Pharmacokinetics, 62(2), pp. 277–295. Available at: https://doi.org/10.1007/s40262-022-01194-3.

Hamusonde, Kalongo et al. (2023) ‘Triggers of Change in Sexual Behavior Among People With HIV: The Swiss U = U Statement and COVID-19 Compared’, Journal of Infectious Diseases, 227(3), pp. 407–411. Available at: https://doi.org/10.1093/infdis/jiac459.

Hodge, Daryl et al. (2023) ‘Prevalence of Potentially Clinically Significant Drug-Drug Interactions with Antiretrovirals Against HIV over Three Decades: A Systematic Review of the Literature’, Journal of Acquired Immune Deficiency Syndromes, 92(2), pp. 97–105. Available at: https://doi.org/10.1097/QAI.0000000000003122.

Bettonte S, Berton M and Marzolini C (2023) ‘What is the significance of the pharmacokinetic profile and potential drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine?’, Expert Opinion on Drug Metabolism and Toxicology, 19(5). Available at: https://doi.org/10.1080/17425255.2023.2223961.

Thoueille, P. et al. (2023) ‘Real-World Trough Concentrations and Effectiveness of Long-Acting Cabotegravir and Rilpivirine: A Multicenter Prospective Observational Study in Switzerland’. Elsevier BV. Available at: https://doi.org/10.2139/ssrn.4584084.

Aebi-Popp K et al. (2022) ‘Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study’, Journal of Antimicrobial Chemotherapy, 77(12), pp. 3436–3442. Available at: https://doi.org/10.1093/jac/dkac337.

Bick, Alexander G. et al. (2022) ‘Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV (Scientific Reports, (2022), 12, 1, (577), 10.1038/s41598-021-04308-2)’, Scientific Reports, 12(1). Available at: https://doi.org/10.1038/s41598-022-16151-0.

Bick, Alexander G. et al. (2022) ‘Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV’, Scientific Reports, 12(1). Available at: https://doi.org/10.1038/s41598-021-04308-2.

Marzolini C et al. (2022) ‘Recommendations for the Management of Drug–Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications’, Clinical Pharmacology and Therapeutics, 112(6), pp. 1191–1200. Available at: https://doi.org/10.1002/cpt.2646.

Catho G et al. (2022) ‘Impact of interactive computerised decision support for hospital antibiotic use (COMPASS): an open-label, cluster-randomised trial in three Swiss hospitals’, The Lancet Infectious Diseases, 22(10), pp. 1493–1502. Available at: https://doi.org/10.1016/S1473-3099(22)00308-5.

Berton M et al. (2022) ‘Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models’, Clinical Pharmacokinetics, 61(9), pp. 1251–1270. Available at: https://doi.org/10.1007/s40262-022-01132-3.

Franchini F et al. (2022) ‘Collaborative Challenges of Multi-Cohort Projects in Pharmacogenetics—Why Time Is Essential for Meaningful Collaborations’, JMIR Formative Research, 6(9), p. e36759. Available at: https://doi.org/10.2196/36759.

Jakeman, Bernadette et al. (2022) ‘Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus’, Open Forum Infectious Diseases, 9(9). Available at: https://doi.org/10.1093/ofid/ofac457.

Ryom L et al. (2022) ‘Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021’, HIV Medicine, 23(8), pp. 849–858. Available at: https://doi.org/10.1111/hiv.13268.

Girardin F et al. (2022) ‘Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19’, Clinical Microbiology and Infection, 28(8), pp. 1044–1046. Available at: https://doi.org/10.1016/j.cmi.2022.03.030.

Thoueille P et al. (2022) ‘Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland’, Pharmaceutics, 14(8). Available at: https://doi.org/10.3390/pharmaceutics14081588.

Otten LS et al. (2022) ‘Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer’, European Respiratory Review, 31(164). Available at: https://doi.org/10.1183/16000617.0004-2022.

Stader F and Marzolini C (2022) ‘Sex-related pharmacokinetic differences with aging’, European Geriatric Medicine, 13(3), pp. 559–565. Available at: https://doi.org/10.1007/s41999-021-00587-0.

Balakrishna, Suraj et al. (2022) ‘Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study’, Journal of Infectious Diseases, 225(9), pp. 1592–1600. Available at: https://doi.org/10.1093/infdis/jiab573.

Marzolini C et al. (2022) ‘Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions’, Annals of Internal Medicine, 175(5). Available at: https://doi.org/10.7326/M22-0281.

Schoepf, Isabella C. et al. (2022) ‘Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over > 17 Years’, Journal of Infectious Diseases, 225(9), pp. 1581–1591. Available at: https://doi.org/10.1093/infdis/jiab603.

Zino L et al. (2022) ‘Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV’, Clinical Pharmacokinetics, 61(5), pp. 619–635. Available at: https://doi.org/10.1007/s40262-022-01120-7.

Bettonte S, Berton M and Marzolini C (2022) ‘Magnitude of Drug–Drug Interactions in Special Populations’, Pharmaceutics, 14(4). Available at: https://doi.org/10.3390/pharmaceutics14040789.

Hachfeld A. et al. (2022) ‘Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS)’, HIV Medicine, 23(4), pp. 417–425. Available at: https://doi.org/10.1111/hiv.13255.

Jacobs TG et al. (2022) ‘Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: Implications for use in people living with HIV’, Journal of Antimicrobial Chemotherapy, 77(3), pp. 568–573. Available at: https://doi.org/10.1093/jac/dkab412.

Marzolini C et al. (2022) ‘Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection’, Clinical Pharmacokinetics, 61(3), pp. 339–346. Available at: https://doi.org/10.1007/s40262-021-01098-8.

Marzolini C et al. (2022) ‘Fluvoxamine for the treatment of COVID-19’, The Lancet Global Health, 10(3). Available at: https://doi.org/10.1016/S2214-109X(21)00592-1.

Stader F et al. (2022) ‘Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients’, Clinical Pharmacology and Therapeutics, 111(3), pp. 579–584. Available at: https://doi.org/10.1002/cpt.2402.

Chiesa A.F. et al. (2022) ‘Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study’, Antiviral Therapy, 27(1). Available at: https://doi.org/10.1177/13596535211068613.

Jakeman B et al. (2022) ‘Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: A prospective cohort study’, Journal of Antimicrobial Chemotherapy, 77(2), pp. 492–499. Available at: https://doi.org/10.1093/jac/dkab386.

Scherrer AU et al. (2022) ‘Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)’, International Journal of Epidemiology, 51(1), pp. 33–34J. Available at: https://doi.org/10.1093/ije/dyab141.

Duran Ramirez JJ et al. (2022) ‘Increasing Frequency and Transmission of HIV-1 Non-B Subtypes among Men Who Have Sex with Men in the Swiss HIV Cohort Study’, Journal of Infectious Diseases, 225(2), pp. 306–316. Available at: https://doi.org/10.1093/infdis/jiab360.

Chaudron, S. E. et al. (2022) ‘A systematic molecular epidemiology screen reveals numerous human immunodeficiency virus (HIV) type 1 superinfections in the Swiss HIV Cohort Study’, J Infect Dis, 226(7), pp. 1256–1266. Available at: https://doi.org/10.1093/infdis/jiac166.

Gussago S et al. (2021) ‘Simultaneous Propionibacterium avidum and Propionibacterium acnes Chronic Periprosthetic Hip Joint Infection: A Case Report.’, 13(12). Available at: https://doi.org/10.7759/cureus.20771.

Hovaguimian, Frédérique et al. (2021) ‘Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis’, Nature Communications, 12(1). Available at: https://doi.org/10.1038/s41467-021-21485-w.

Muller, Christina K. S. et al. (2021) ‘Immunophenotypic characterization of TCR γδ T cells and MAIT cells in HIV-infected individuals developing Hodgkin’s lymphoma’, Infectious Agents and Cancer, 16(1). Available at: https://doi.org/10.1186/s13027-021-00365-4.

Rüeger, Sina et al. (2021) ‘The influence of human genetic variation on Epstein–Barr virus sequence diversity’, Scientific Reports, 11(1). Available at: https://doi.org/10.1038/s41598-021-84070-7.

Rüeger, Sina et al. (2021) ‘Author Correction: The influence of human genetic variation on Epstein–Barr virus sequence diversity (Scientific Reports, (2021), 11, 1, (4586), 10.1038/s41598-021-84070-7)’, Scientific Reports, 11(1). Available at: https://doi.org/10.1038/s41598-021-87274-z.

Schoepf IC et al. (2021) ‘Coronary artery disease-associated and longevity-associated polygenic risk scores for prediction of coronary artery disease events in persons living with human immunodeficiency virus: The swiss hiv cohort study’, Clinical Infectious Diseases, 73(9), pp. 1597–1604. Available at: https://doi.org/10.1093/cid/ciab521.

Stader F, Battegay M and Marzolini C (2021) ‘Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir’, Clinical Pharmacology and Therapeutics, 110(5), pp. 1231–1239. Available at: https://doi.org/10.1002/cpt.2221.

Allavena C and Marzolini C (2021) ‘Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug–drug interactions?’, The Lancet Healthy Longevity, 2(10). Available at: https://doi.org/10.1016/S2666-7568(21)00227-0.

Balakrishna, Suraj et al. (2021) ‘Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study’, PLoS Computational Biology, 17(10). Available at: https://doi.org/10.1371/journal.pcbi.1009529.

Pyngottu A. et al. (2021) ‘Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment’, Clinical Infectious Diseases, 73(7), pp. E2134–E2141. Available at: https://doi.org/10.1093/cid/ciaa1614.

Kovari H. et al. (2021) ‘Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study’, HIV Medicine, 22(7), pp. 623–628. Available at: https://doi.org/10.1111/hiv.13106.

Treglia G et al. (2021) ‘Prevalence and significance of hypermetabolic lymph nodes detected by 2-[18F]FDG PET/CT after COVID-19 vaccination: A systematic review and a meta-analysis’, Pharmaceuticals, 14(8). Available at: https://doi.org/10.3390/ph14080762.

Courlet P et al. (2021) ‘Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs’, European Journal of Clinical Pharmacology, 77(7), pp. 979–987. Available at: https://doi.org/10.1007/s00228-020-03060-2.

Hodge D et al. (2021) ‘Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine’, Clinical Pharmacokinetics, 60(7), pp. 835–853. Available at: https://doi.org/10.1007/s40262-021-01005-1.

Santos, Galia et al. (2021) ‘The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland’, International Journal of STD and AIDS, 32(8), pp. 729–739. Available at: https://doi.org/10.1177/0956462420987434.

Stoira E, Chiesa AF and Elzi L (2021) ‘‘High prevalence of heterotopic ossification in critically ill patients with severe COVID-19’ – Author’s reply’, Clinical Microbiology and Infection, 27(7). Available at: https://doi.org/10.1016/j.cmi.2021.02.004.

Stoira E et al. (2021) ‘High prevalence of heterotopic ossification in critically ill patients with severe COVID-19’, 27(7). Available at: https://doi.org/10.1016/j.cmi.2020.12.037.

Dietrich, Léna G et al. (2021) ‘Rapid Progression of Kidney Dysfunction in People Living with HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores’, Journal of Infectious Diseases, 223(12), pp. 2145–2153. Available at: https://doi.org/10.1093/infdis/jiaa695.

Chammartin F et al. (2021) ‘Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study’, Annals of Internal Medicine, 174(6), pp. 768–776. Available at: https://doi.org/10.7326/M20-5226.

Surial, Bernard et al. (2021) ‘Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: A Cohort Study’, Annals of Internal Medicine, 174(6), pp. 758–767. Available at: https://doi.org/10.7326/M20-4853.

Treglia G et al. (2021) ‘PET findings after COVID-19 vaccination: “Keep Calm and Carry On”’, Clinical and Translational Imaging, 9(3). Available at: https://doi.org/10.1007/s40336-021-00430-3.

Reichmuth M.L. et al. (2021) ‘Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission’, HIV Medicine, 22(5), pp. 346–359. Available at: https://doi.org/10.1111/hiv.13030.

Bentzon, A.K. et al. (2021) ‘Healthcare delivery for HIV-positive people with tuberculosis in Europe’, HIV Medicine, 22(4), pp. 283–293. Available at: https://doi.org/10.1111/hiv.13016.